Dendritic cell transfer for cancer immunotherapy.

No abstract is available for this paper.

• Publication year

  2022

• Venue

  International Review of Cell and Molecular Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/bs.ircmb.2022.03.003PMID 35798506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A genotype-phenotype screening system using conditionally immortalized immature dendritic cells

  2021cited by this paper
• Dendritic cell migration in inflammation and immunity

  2021cited by this paper
• Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

  2021cited by this paper
• mRNA in cancer immunotherapy: beyond a source of antigen

  2021cited by this paper
• CRISPR-based functional genomics in human dendritic cells

  2020cited by this paper
• Detection of immunogenic cell death and its relevance for cancer therapy

  2020cited by this paper
• Exosome-based immunotherapy: a promising approach for cancer treatment

  2020cited by this paper
• Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death

  2020cited by this paper
• Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

  2020cited by this paper
• Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

  2020cited by this paper
• Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

  2020cited by this paper
• PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer

  2020cited by this paper
• Naringenin Enhances the Antitumor Effect of Therapeutic Vaccines by Promoting Antigen Cross-Presentation

  2019cited by this paper
• A method for the generation of large numbers of dendritic cells from CD34+ hematopoietic stem cells from cord blood

  2019cited by this paper
• Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response

  2019cited by this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cited by this paper
• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

  2019cited by this paper
• The global pipeline of cell therapies for cancer

  2019cited by this paper
• The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

  2019cited by this paper
• Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

  2019cited by this paper
• Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review

  2019cited by this paper
• Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

  2019cited by this paper
• Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors

  2019cited by this paper
• Anti-tumor immunity controlled through mRNA m6A and YTHDF1 in dendritic cells

  2019cited by this paper
• Human dendritic cell subsets: an update

  2018cited by this paper
• An Update on Immunotherapy for Solid Tumors: A Review

  2018cited by this paper
• Genealogy, Dendritic Cell Priming, and Differentiation of Tissue-Resident Memory CD8+ T Cells

  2018cited by this paper
• A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

  2018cited by this paper
• Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

  2018cited by this paper
• Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?

  2018cited by this paper
• NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

  2018cited by this paper
• A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia

  2018cited by this paper
• CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review

  2018cited by this paper
• Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

  2018cited by this paper
• A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

  2018cited by this paper
• Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma

  2018cited by this paper
• Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues

  2017cited by this paper
• Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross‐priming through Signal Regulatory Protein &agr; Signaling

  2017cited by this paper
• Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis

  2017cited by this paper
• Qualitative differences in T‐cell activation by dendritic cell‐derived extracellular vesicle subtypes

  2017cited by this paper
• Engulfment signals and the phagocytic machinery for apoptotic cell clearance

  2017cited by this paper
• Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model

  2017cited by this paper
• A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

  2017cited by this paper
• Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy

  2017cited by this paper
• CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.

  2017cited by this paper
• Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration

  2017cited by this paper
• GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family

  2017cited by this paper
• Therapeutic blockade of Foxp3 in experimental breast cancer models

  2017cited by this paper
• Dendritic cell-based immunotherapy

  2016cited by this paper
• Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro

  2016cited by this paper
• Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

  2016cited by this paper
• Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

  2016cited by this paper
• Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

  2016cited by this paper
• Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

  2016cited by this paper
• Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis

  2015cited by this paper
• siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice

  2015cited by this paper
• Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

  2015cited by this paper
• Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

  2015cited by this paper
• TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma

  2015cited by this paper
• Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

  2015cited by this paper
• Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

  2015cited by this paper
• Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.

  2014cited by this paper
• Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

  2014cited by this paper
• Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer

  2014cited by this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cited by this paper
• Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

  2014cited by this paper
• Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

  2014cited by this paper
• A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

  2014cited by this paper
• Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs.

  2014cited by this paper
• Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?

  2014cited by this paper
• How to generate large numbers of CD103+ dendritic cells.

  2014cited by this paper
• Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial

  2014cited by this paper
• Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.

  2013cited by this paper
• Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer

  2013cited by this paper
• Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

  2013cited by this paper
• Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

  2013cited by this paper
• Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy

  2013cited by this paper
• The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

  2013cited by this paper
• Generation of Inducible Immortalized Dendritic Cells with Proper Immune Function In Vitro and In Vivo

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

  2012cited by this paper
• Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors.

  2012cited by this paper
• Novel Murine Dendritic Cell Lines: A Powerful Auxiliary Tool for Dendritic Cell Research

  2012cited by this paper
• Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

  2011cited by this paper
• Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

  2011cited by this paper
• Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

  2011cited by this paper
• Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis

  2011cited by this paper
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

  2010cited by this paper
• Mature dendritic cells use endocytic receptors to capture and present antigens

  2010cited by this paper
• Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.

  2010cited by this paper
• siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

  2010cited by this paper
• Dendritic Cells (DCs) Can Be Successfully Generated From Leukemic Blasts in Individual Patients With AML or MDS: An Evaluation of Different Methods

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Precise conditional immortalization of mouse cells using tetracycline‐regulated SV40 large T‐antigen

  2010cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

  2009cited by this paper
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

  2009cited by this paper
• Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

  2008cited by this paper

• Pharmacological screening to identify potential regulators of antigen presentation by dendritic cells.

  2025cites this paper
• PD-L1+ macrophages suppress T cell-mediated anticancer immunity

  2024cites this paper
• Tug of war: Understanding the dynamic interplay of tumor biomechanical environment on dendritic cell function

  2024cites this paper
• Broad applicability of the Goldspire™ platform for the treatment of solid tumors.

  2024cites this paper
• Trial watch: anticancer vaccination with dendritic cells

  2024cites this paper
• Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference

  2023cites this paper
• Dual impact of radiation therapy on tumor-targeting immune responses.

  2023cites this paper
• Histamine antagonists promote cancer immunosurveillance

  2023cites this paper
• A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma

  2023cites this paper
• Type I interferon and cancer

  2023cites this paper
• Molecular determinants of immunogenic cell death elicited by radiation therapy

  2023cites this paper